PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways  by Zhang, Jifeng et al.
PDGF induces osteoprotegerin expression in vascular smooth muscle
cells by multiple signal pathways
Jifeng Zhanga;1, Mingui Fua;1, David Mylesa;1, Xiaojun Zhua, Jie Dub, Xu Caoc,
Yuqing E. Chena;
aCardiovascular Research Institute, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310, USA
bCardiovascular Division, Kansas University Medical Center, Kansas City, KS 66160, USA
cDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Received 19 April 2002; revised 7 May 2002; accepted 9 May 2002
First published online 29 May 2002
Edited by Beat Imhof
Abstract Osteoprotegerin (OPG) is a key regulator of
osteoclastogenesis. Recent reports suggest that OPG may
function as a protector of arterial calcification and survival of
endothelial cells. However, the role and expression of OPG in
vascular wall is unclear. Here we report that OPG was highly
expressed in vascular smooth muscle cells (VSMC) but not in
endothelial cells. Platelet-derived growth factor (PDGF), basic
fibroblast growth factor, angiotensin II, tumor necrosis factor K
and interleukin-1L upregulated OPG expression in VSMC.
Moreover, inhibition of phosphatidylinositol 3-kinase/Akt or
P38-signal pathway abrogated PDGF-induced OPG expression.
Our results suggest that OPG may be an important determinant
of vascular homeostasis. . 2002 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Intrduction
Osteoprotegerin (OPG, also known as osteoclastogenesis
inhibitory factor, OCIF) is a member of the tumor necrosis
factor (TNF) receptor superfamily which binds to the receptor
activator of nuclear factor-UB (NF-UB) ligand (RANKL),
thereby neutralizing its functions and negatively regulate os-
teoclast di¡erentiation, activity and survival [1^3]. The iden-
ti¢cation of the OPG/RANKL/RANK system as the determi-
nant of osteoclastogenesis represents a major advance in bone
biology. Targeted deletion of OPG in mice resulted in severe,
early-onset osteoporosis and marked calci¢cation of the aorta
and renal arteries [3,4]. Although it has been documented that
OPG is expressed abundantly in the vascular wall [5,6], the
role of OPG in the vascular wall is poorly understood. In
human populations, OPG is associated with a higher inci-
dence of arterial calci¢cation, a component of atherosclerotic
lesions [7,8]. In addition, recent reports have shown that OPG
administration prevents vessels from calci¢cation induced by
warfarin and vitamin D [9], and protects endothelial cells
from apoptosis [10]. These ¢ndings suggest that OPG may
have a protective role in the vascular system.
Platelet-derived growth factor (PDGF) is a potent mitogen
and chemoattractant that functions as an important mediator
in the pathogenesis of vascular disease [11,12]. Activation of
PDGF receptor in vascular smooth muscle cells (VSMC) can
activate several signaling pathways, including p38-, mitogen
activated protein kinase (MAPK)- and phosphatidylinositol 3
(PI3)-kinase-mediated signal pathways, which transduce the
signals into the nucleus and stimulate VSMC proliferation
and migration [13,14].
In the present study, we document for the ¢rst time that
OPG is highly expressed in human VSMC, but not vascular
endothelial cells, and that PDGF induces OPG expression by
multiple signal pathways including PI3-kinase/Akt- and P38-
dependent pathways in VSMC. Our data implicate that OPG
can function as an important determinant of vascular homeo-
stasis in addition to bone biology.
2. Materials and methods
2.1. Materials
PDGF-BB, basic ¢broblast growth factor (bFGF), angiotensin II
(AngII), tumor necrosis factor K (TNFK) and interleukin-1L (IL-1L)
were purchased from Sigma (St. Louis, MO, USA). Ly294002,
SB202190 and U0126 were obtained from BioMol Research Labora-
tories (Plymouth Meeting, PA, USA). Anti-human OPG antibody was
purchased from RpD Systems (Minneapolis, MN, USA). Cell culture
medium and phosphate-bu¡ered saline (PBS) were purchased from
Invitrogen (Carlsbad, CA, USA).
2.2. Cell culture and stimulation
Human aortic smooth muscle cells (HASMC) and human umbelial
vein endothelial cells (HUVEC) were purchased from Biowhittaker
(San Diego, CA, USA). The HASMCs were cultured in smooth
muscle cell growth medium-2 containing 5% fetal bovine serum
(FBS), 2 ng/ml human bFGF, 0.5 ng/ml human epidermal growth
factor, 50 Wg/ml gentamicin, 50 ng/ml amphotericin-B, and 5 Wg/ml
bovine insulin. The HUVECs were cultured in EGM-2 containing 5%
FBS, 2 ng/ml human bFGF, 0.5 ng/ml human epidermal growth fac-
tor, 50 Wg/ml gentamicin, 50 ng/ml amphotericin-B, and 5 Wg/ml bo-
vine insulin. For stimulation experiments, early passages (¢ve to sev-
en) of HASMC were grown to 80^90% con£uence and made quiescent
by serum starvation (0.4% FBS) for at least 24 h. The LY294002,
SB202190 and U0126 inhibitors were added 30 min before the addi-
tion of human recombinant PDGF-BB, bFGF, AngII, TNFK, or IL-
1L. The rat vascular smooth muscle cell line (A7r5) was purchased
from ATCC (Cat# CRL-1444, Manassas, VA, USA) and cultured in
Dulbecco’s modi¢ed Eagle’s medium containing 10% FBS.
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2.3. Northern and Western blot analyses
Both Northern and Western blot analyses were performed as pre-
viously described [15].
2.4. Transient transfection and luciferase assays
Transient transfection was performed with 0.5 Wg of total DNA per
well and LipofectAMINE (Invitrogen) according to the manufactur-
er’s instructions. Brie£y, cultured A7r5 achieving 70^80% con£uence
in 12-well plates were cotransfected with 400 ng of the expression
vector containing the luciferase reporter gene driven by a V1.1 kb
OPG promoter [17] and 100 ng of the green £uorescent protein (GFP)
expression vector (Clontech), which was used as the control for trans-
fection e⁄ciency. 24 h after transfection, the cells were washed twice
with PBS and subsequently cultured for 24 h in Optium-MEM (In-
vitrogen). After incubating with 20 ng/ml of PDGF for 6 h, the cells
were assessed for luciferase activity using the luciferase assay kit
(Promega). The luciferase activity was measured by a luminometer
(Victor II, Perkin Elmer) and normalized by GFP level.
2.5. Adenovirus preparation and infection
Adenovirus was prepared as previously described [15]. For the gen-
eration of recombinant adenovirus encoding dominant negative IUB
(named as Ad-IUBDN; Du et al., unpublished data), an IUB mutant
with lysine residues at 21 and 22 were converted to arginines as pre-
viously described [18]. The virus was puri¢ed by CsCl gradient and
¢nal yields were generally 1010 to 1012 plaque-forming units (PFU)/ml.
In this study, the VSMCs were infected with adenovirus vectors at
V5 PFU/cell. The cells were subjected to experiments 24^48 h after
infection.
2.6. Statistical analysis
Each experimental condition was tested in triplicate, and each ex-
periment was repeated a minimum of three times. Statistical analyses
were performed by ANOVA or unpaired 2-tailed Student t-test. Data
are presented as meanTS.E.M. The value for P6 0.05 was considered
signi¢cant.
3. Results
3.1. Expression of OPG/RANK/RANKL in HASMC and
HUVEC
To explore whether the OPG/RANK/RANKL system exists
in vascular cells, we ¢rstly measured the mRNA levels of
OPG, RANK and RANKL in HASMC and HUVEC by
Northern blot analyses, respectively. As shown in Fig. 1,
OPG was highly expressed in HASMC, whereas it was unde-
tectable in HUVEC. Although RANK can be detected in
HASMC and HUVEC, its mRNA levels were quite lower
than OPG. In contrast, the RANKL mRNA was undetectable
in both HASMC and HUVEC by Northern blot analysis.
3.2. Growth factors and cytokines induce OPG expression in
HASMC
The growth factors and cytokines such as PDGF, bFGF,
AngII, TNFK and IL-1L are critical determinants of vascular
pathogenesis. To determine whether OPG expression is regu-
lated by these factors in HASMC, quiescent cells were stimu-
lated with PDGF, bFGF, AngII, TNFK and IL-1L for 6 h,
and the mRNA levels of OPG were analyzed by Northern
Fig. 1. The mRNA levels of OPG/RANK/RANKL in HASMC and
HUVEC. Total RNA was isolated from three £asks of HASMC
and three £asks of HUVEC for Northern blot analyses. Representa-
tive Northern blots show the mRNA levels of OPG, RANK or
RANKL. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as the control for equal loading. Three independent ex-
periments showed similar results.
Fig. 2. OPG mRNA expression is induced by PDGF, bFGF, AngII,
TNFK and IL-1L in HASMC. The cells were made quiescent by se-
rum starvation (0.4% FBS) for 24 h, and then treated with or with-
out 20 ng/ml PDGF, bFGF (25 ng/ml), AngII (3U1037 mol/l)
TNFK (10 ng/ml) and IL-1L (10 ng/ml) for 6 h. The OPG mRNA
levels were analyzed by Northern blot analyses. GAPDH was used
as the control for equal loading. Three independent experiments
showed similar results.
Fig. 3. PDGF induces OPG expression in a time- and dose-depen-
dent manner in HASMC. The cells were made quiescent by serum
starvation (0.4% FBS) for 24 h, and then treated with 20 ng/ml
PDGF for di¡erent time periods as indicated (A) or with an in-
creasing concentration of PDGF for 6 h (B). The OPG mRNA lev-
els were analyzed by Northern blot analyses. C: The cell culture
medium was collected and concentrated with a Biomax Column.
OPG protein levels in HASMC culture medium were examined by
Western blot analyses. The Coomassie blue-stained gel indicates
equal protein loading. Three independent experiments showed simi-
lar results.
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blot analyses. As shown in Fig. 2, all of these factors used
above signi¢cantly induced OPG expression in HASMC.
3.3. Time-course and dose-e¡ect of PDGF on OPG expression
in HASMC
To further con¢rm the e¡ect of PDGF on the expression of
OPG mRNA, di¡erent concentrations or di¡erent times of
PDGF stimulation were examined in HASMC. As shown in
Fig. 3A, 20 ng/ml PDGF induced the OPG mRNA expression
in HASMC in a time-dependant manner which peaks at 6 h.
In addition, PDGF also induced OPG mRNA expression in a
dose-dependent manner (Fig. 3B). A signi¢cant increase in
OPG mRNA was observed at a concentration of 10 ng/ml
PDGF while the maximal increase was achieved at 50 ng/
ml. Furthermore, we documented that the matured OPG pro-
tein in the culture medium of HASMC was very low and
signi¢cantly increased by PDGF stimulation (Fig. 3C).
To further examine whether PDGF-induced OPG expres-
sion was regulated at transcriptional level, we transiently
transfected aV1.1 kb OPG promoter/luciferase reporter con-
struct into rat vascular smooth muscle cells (A7r5). A GFP
expression vector was used for control of transfection e⁄-
ciency. As shown in Fig. 4, PDGF stimulation increased
OPG promoter activity by Vthree-fold.
3.4. PDGF induces OPG expression through PI3-kinase/Akt
and p38/MAPK signaling pathway in HASMC
To investigate the signaling pathways mediating PDGF-in-
duced OPG expression in HASMC, the cells were treated with
20 ng/ml PDGF for 6 h after pre-incubation with LY294002
(50 WM, a PI3-kinase inhibitor), SB202190 (25 WM, a p38
kinase inhibitor), or U0126 (10 WM, a mitogen-activated pro-
tein kinase/extracellular signal-regulated kinase (MEK) inhib-
itor). As shown in Fig. 5, inhibition of PI3-kinase or p38-
MAPK completely blocked the e¡ect of PDGF (P6 0.01).
Although inhibition of MEK signi¢cantly attenuated the ef-
fect of PDGF-induced OPG expression by 72T 8.5%
(P6 0.01), U0126 alone reduced the basal level of OPG ex-
pression in VSMC by 54T 2.1% (P6 0.01). Taken together,
these results suggested that OPG expression is regulated by
PDGF in VSMC through several major signaling pathways
including PI3-kinase/AKT and p38/MAPK.
To further con¢rm that the PI3-kinase/Akt pathway is in-
volved in PDGF-induced OPG gene expression in VSMC, we
selectively blocked this signaling pathway by using Ad-
Fig. 4. PDGF stimulation activates OPG promoter. A V1.1 kb
OPG promoter/luciferase reporter construct and a GFP expression
vector were cotransfected into rat vascular smooth muscle cells
(A7r5). 24 h after transfection, cells were treated with Optium-
MEM for 24 h and then stimulated with 20 ng/ml PDGF for 6 h.
The luciferase activity normalized by GFP activity was expressed in
relative units to PDGF stimulation (meanTS.E.M., n=6). An arbi-
trary value of 1 was assigned to GFP control.
Fig. 5. Both PI3-kinase and p38 kinase inhibitor block PDGF-in-
duced OPG expression in HASMC. The cells were treated with
PDGF (20 ng/ml) for 6 h after pre-incubation with LY294002 (50
Wmol/l, a PI3-kinase inhibitor), SB202190 (25 Wmol/l, a p38 kinase
inhibitor) or U0126 (10 Wmol/l, a MEK inhibitor) for 30 min. OPG
mRNA levels were determined by Northern blot analyses. A repre-
sentative Northern blot (top) and the quantitative graph (bottom)
of three experiments are shown. Values were normalized by
GAPDH and expressed as meanTS.E.M. (n=3, *P6 0.01).
Fig. 6. Overexpression of a dominant negative p85 of PI3-kinase or
protein kinase B (Akt) blocks PDGF-induced OPG expression in
HASMC. The cells at 80^90% con£uence were infected with the ad-
enovirus encoding a dominant negative p85 of PI3-kinase, Akt or
IUB at 5 PFU/cell for 2 h. Following 24 h in growth medium, the
cells were made quiescent by serum starvation (0.4% FBS) for 24 h,
then treated with 20 ng/ml PDGF for 6 h. A representative North-
ern blot is shown in the top panel. The average values of OPG
mRNA normalized by GAPDH (bottom panel) are presented as
meansTS.E.M. (n=3, *P6 0.01 and **P6 0.05).
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p85DN, an adenoviral vector containing a dominant negative
mutant p85 of PI3-kinase as previously described [15], or Ad-
AktDN, a recombinant adenovirus which contains a domi-
nant negative form of Akt. Inhibition of the PI3-kinase/Akt
pathway using this approach e¡ectively prevented PDGF-in-
duced OPG gene expression in VSMC (Fig. 6). However,
OPG expression was not a¡ected by the control adenovirus
(Ad-GFP) infection in VSMC (data not shown). With the
same approach, we used an adenovirus vector encoding a
constitutively active form of IUB to examine if NF-UB is in-
volved in PDGF-induced OPG gene expression in VSMC
since NF-UB is a well-de¢ned Akt target. As shown in Fig.
6, blockade of the NF-UB activation does not a¡ect PDGF-
induced OPG expression in VSMC. Taken together, these
data documented that both PI3-kinase and Akt are involved
in PDGF-induced OPG gene expression. However, NF-UB is
not the downstream mediator of Akt on PDGF-induced OPG
gene expression.
4. Discussion
Although OPG expression has been extensively studied in
osteoblast, little is known about the regulation of OPG ex-
pression in VSMC. In the present study, we documented that
OPG is highly expressed in HASMC but undetectable in HU-
VEC, and that RANK but not RANKL is expressed in both
cells. In addition, we demonstrated that PDGF induces OPG
expression in a time- and dose-dependent manner and through
several signaling pathways including PI3-kinase/AKT and
p38/MAPK. Furthermore, we found that multiple growth fac-
tors and cytokines such as PDGF, bFGF, AngII, TNFK and
IL-1L could induce OPG gene expression in VSMC. Taken
together, our data suggested that OPG plays important roles
in the cardiovascular system.
The OPG/RANK/RANKL system is a critical determinant
of maintenance of skeletal integrity. OPG functions as a solu-
ble decoy receptor for RANKL and regulates bone mass by
inhibiting osteoclast di¡erentiation and activation [1^3]. How-
ever, mice with targeted ablation of OPG not only developed
severe osteoporosis due to markedly increased osteoclast for-
mation and subsequent bone resorption, but also developed
profound calci¢cation in large arteries, marked intimal and
medial proliferation [3]. Thus, OPG may play a signi¢cant
role in the vasculature. Indeed, a recent study showed that
OPG is an important survival factor for endothelial cells
[10], however, the mechanism is not clear. To date, OPG
not only functions as a decoy receptor for RANKL, but
also for TNF-related apoptosis-inducing ligand (TRAIL)
[16]. Moreover, it has been well documented that TRAIL is
secreted from VSMC and potently induces apoptosis of endo-
thelial cells. Therefore, further studies would be interesting to
examine whether OPG functions as a survival factor of endo-
thelial cells by inhibiting the TRAIL signaling pathway.
The present study documented that OPG expression is
regulated by PDGF in VSMC through several major signaling
pathways including PI3-kinase/AKT and p38/MAPK. How-
ever, the downstream e¡ectors (i.e. transcriptional factors)
that directly regulate OPG transcription in VSMC are not
yet identi¢ed. Using computerized analysis, we found that
there are several transcriptional factor binding sites such as
AP1, NF-UB and cbfa1 in the human OPG promoter (data
not shown). To further characterize the downstream targets of
PI3-kinase/AKT on the regulation of PDGF-induced OPG
expression, we examined the role of NF-UB. However, our
data suggested that NF-UB is not involved in PDGF-induced
OPG expression in VSMC. We are currently investigating
other transcriptional factors, but a systematic deletion map-
ping of PDGF-response elements in the OPG promoter may
be necessary to understand this mechanism, a study which is
obviously beyond the objectives of this paper.
We have documented that the OPG is expressed and regu-
lated by growth factors and cytokines in VSMC, however, the
cells used in this present study were obtained from commer-
cially available cultured cells. What are the levels of OPG
expression in normal and diseased vascular walls? To address
this question, we recently examined the expression levels of
OPG in the rat aorta before and after balloon-injury using
quantitative reverse transcription-polymerase chain reaction.
Our data suggested that OPG expression is expressed in nor-
mal vessel walls and increased after balloon-injury (data not
shown). Interestingly, a recent paper documented that OPG is
expressed not only in non-diseased vessel wall but also in the
early atherosclerotic lesions [8]. Taken together, OPG is ex-
pressed in VSMC in vivo and may play an important role in
the development of atherosclerosis.
In conclusion, the identi¢cation of potential novel functions
of OPG in VSMC will de¢nitely spur new interest in the study
of OPG function. Further studies are required to elucidate the
roles of OPG in the cardiovascular system.
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